KIR Ligands and Prediction of Relapse after Unrelated Donor Hematopoietic Cell Transplantation for Hematologic Malignancy  Katharine C. Hsu, Ted Gooley, Mari Malkki, Clara Pinto-Agnello, Bo Dupont, Jean-Denis Bignon, Martin Bornhäuser, Frank Christiansen, Alois Gratwohl, Yasuo Morishima, Machteld Oudshoorn, Olle Ringden, Jon J. van Rood, Effie Petersdorf  Biology of Blood and Marrow Transplantation  Volume 12, Issue 8, Pages 828-836 (August 2006) DOI: 10.1016/j.bbmt.2006.04.008 Copyright © 2006 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Probability of relapse in HLA-matched (A) or HLA-mismatched (B) patients lacking KIR ligand (broken line) or not lacking KIR ligand (solid line). Lack of recipient KIR ligand was defined as HLA-C group 1, group 2, or Bw6 homozygosity. Biology of Blood and Marrow Transplantation 2006 12, 828-836DOI: (10.1016/j.bbmt.2006.04.008) Copyright © 2006 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Probability of relapse in leukemia patients lacking (broken line) or not lacking (solid line) KIR ligand. A. Effect of missing ligand in AML. B. Effect of missing ligand in CML and ALL. The relative difference in the probability of relapse between the missing and non-missing groups was comparable in the AML and non-AML groups, even though the absolute difference in probabilities was larger in the AML group due to a higher overall probability of relapse. Biology of Blood and Marrow Transplantation 2006 12, 828-836DOI: (10.1016/j.bbmt.2006.04.008) Copyright © 2006 American Society for Blood and Marrow Transplantation Terms and Conditions